CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms

作者: Catherine A Wassenaar , Qian Zhou , Rachel F Tyndale

DOI: 10.2217/PGS.15.156

关键词:

摘要: CYP2A6 genotyping is of clinical importance--CYP2A6 gene variants influence nicotine metabolism and are associated with dependence, cigarettes per day, smoking cessation the risk for tobacco-associated cancers. also therapeutic drugs, such as anticancer agents, tegafur letrozole. Over years, methods have evolved to incorporate novel circumvent errors resulting from high degree homology between neighboring CYP2A genes. Herein, strategies described commonly genotyped functionally significant alleles including SNPs, small insertions/deletions more complex structural variants. The presented utilize higher throughput SYBR green real-time PCR technology in addition standard thermocycling.

参考文章(54)
Yushu Rao, Ewa Hoffmann, Mohammad Zia, Laurent Bodin, Marilyn Zeman, Edward M. Sellers, Rachel F. Tyndale, Duplications and Defects in the CYP2A6 Gene: Identification, Genotyping, and In Vivo Effects on Smoking Molecular Pharmacology. ,vol. 58, pp. 747- 755 ,(2000) , 10.1124/MOL.58.4.747
T FUKAMI, M NAKAJIMA, R YOSHIDA, Y TSUCHIYA, Y FUJIKI, M KATOH, H MCLEOD, T YOKOI, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clinical Pharmacology & Therapeutics. ,vol. 76, pp. 519- 527 ,(2004) , 10.1016/J.CLPT.2004.08.014
Jill C. Mwenifumbo, Nael Al Koudsi, Man Ki Ho, Qian Zhou, Ewa B. Hoffmann, Edward M. Sellers, Rachel F. Tyndale, Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human Mutation. ,vol. 29, pp. 679- 688 ,(2008) , 10.1002/HUMU.20698
Caryn Lerman, Robert A Schnoll, Larry W Hawk, Paul Cinciripini, Tony P George, E Paul Wileyto, Gary E Swan, Neal l Benowitz, Daniel F Heitjan, Rachel F Tyndale, Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial The Lancet Respiratory Medicine. ,vol. 3, pp. 131- 138 ,(2015) , 10.1016/S2213-2600(14)70294-2
Jill C Mwenifumbo, Qian Zhou, Neal L Benowitz, Edward M Sellers, Rachel F Tyndale, New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics. ,vol. 11, pp. 189- 198 ,(2010) , 10.2217/PGS.09.144
Marià Pitarque, Oliver von Richter, Basbug Oke, Hakan Berkkan, Mikael Oscarson, Magnus Ingelman-Sundberg, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochemical and Biophysical Research Communications. ,vol. 284, pp. 455- 460 ,(2001) , 10.1006/BBRC.2001.4990
Frederick E. Dewey, Megan E. Grove, Cuiping Pan, Benjamin A. Goldstein, Jonathan A. Bernstein, Hassan Chaib, Jason D. Merker, Rachel L. Goldfeder, Gregory M. Enns, Sean P. David, Neda Pakdaman, Kelly E. Ormond, Colleen Caleshu, Kerry Kingham, Teri E. Klein, Michelle Whirl-Carrillo, Kenneth Sakamoto, Matthew T. Wheeler, Atul J. Butte, James M. Ford, Linda Boxer, John P. A. Ioannidis, Alan C. Yeung, Russ B. Altman, Themistocles L. Assimes, Michael Snyder, Euan A. Ashley, Thomas Quertermous, Clinical Interpretation and Implications of Whole-Genome Sequencing JAMA. ,vol. 311, pp. 1035- 1045 ,(2014) , 10.1001/JAMA.2014.1717
Matthew J. Binnington, Andy Z.X. Zhu, Caroline C. Renner, Anne P. Lanier, Dorothy K. Hatsukami, Neal L. Benowitz, Rachel F. Tyndale, CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenetics and Genomics. ,vol. 22, pp. 429- 440 ,(2012) , 10.1097/FPC.0B013E3283527C1C
Jill C. Mwenifumbo, Mark G. Myers, Tamara L. Wall, Shih-Ku Lin, Edward M. Sellers, Rachel F. Tyndale, Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenetics and Genomics. ,vol. 15, pp. 189- 192 ,(2005) , 10.1097/01213011-200503000-00008